A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers
Clinical trial NCT01814839 · COMPLETED
Trial details
- NCT number
- NCT01814839
- Sponsor
- Alnylam Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-03-01
- Primary completion
- 2015-04-01
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.